Do you want to read an article? Please log in or register.
Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: 3-Month Data From a Randomized Phase 3 Trial
Glaucoma and Ocular Pressure
RECOMMENDED
Related content
RECOMMENDED
Glaucoma and Ocular Pressure
24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial
Ophthalmology.
Weinreb RN, Bacharach J, Fechtner RD, Kahook MY, Wirta D, Burmaster S, Meng X, Hubatsch DA
doi: 10.1016/j.ophtha.2018.10.040.
Glaucoma and Ocular PressureOcular Oncology
Effects of Netarsudil on the Corneal Endothelium: Three-Month Findings from a Phase 3 Trial
Ophthalmol Glaucoma
Mundorf T, Mah F, Sheng H, Heah T
doi: 10.1016/j.ogla.2020.04.014
Macular Diseases
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial
JAMA Ophthalmol.
Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, Basu K, Ehrlich JS, Haskova Z, Dugel PU
doi: 10.1001/jamaophthalmol.
Macular DiseasesRetinal DiseasesFurther Publications
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial
JAMA Ophthalmol
Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL, Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group.
doi: 10.1001/jamaophthalmol.2021.4395
Macular Diseases
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial
JAMA Ophthalmol.
Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B, Del Valle Rubido M, Sadikhov S, Szczesny P, Schwab D, Nogoceke E, Weikert R, Fauser S
doi: 10.1001/jamaophthalmol.
Glaucoma and Ocular Pressure
Evaluation of a Primary Open-Angle Glaucoma Prediction Model Using Long-term Intraocular Pressure Variability Data: A Secondary Analysis of 2 Randomized Clinical Trials
JAMA Ophthalmol.
Gordon MO, Gao F, Huecker JB, Miller JP, Margolis M, Kass MA, Migliore S, Torri V, European Glaucoma Prevention Study and the Ocular Hypertension Treatment Study.
doi: 10.1001/jamaophthalmol.2020.1902.
COMMENTED
Macular Diseases
Archway Randomized Phase 3 Trial of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration
★ 2
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Ophthalmology
Holekamp NM, Campochiaro PA, Chang M, Miller D, Pieramici D, Adamis AP, Brittain C, Evans E, Kaufman D, Maass KF, Patel S, Ranade S, Singh N, Barteselli G, Regillo C, Archway Investigators.
doi: 10.1016/j.ophtha.2021.09.016
COMMENTED
Macular Diseases
Randomized Trial of Treat & Extend Ranibizumab With & Without Navigated Laser versus Monthly Dosing for DME: TREX-DME 2 Year Outcomes
Am J Ophthalmol.
Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group
doi: 10.1016/j.ajo.
Glaucoma and Ocular PressureOcular Oncology
The Effects of Phacoemulsification on Intraocular Pressure and Topical Medication Use in Patients With Glaucoma: A Systematic Review and Meta-analysis of 3-Year Data
J Glaucoma.
Armstrong JJ, Wasiuta T, Kiatos E, Malvankar-Mehta M, Hutnik CM.